Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar line70day (< 20) Submitted: 11/12/2012 3:57:59 PM : Outperform Start Price: $10.95 AMRN Score: -114.10

hyertiglyceridemic drug Vasepa approved by FDA needs NCE approval drug has no side affects cash and cash equivalents o $ 215.1M no cash outflow Questions about a take over

Featured Broker Partners


Advertisement